{
}
Novo Nordisk plans to seek regulatory approval for semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) after positive Phase 3 trial results. The study showed significant improvements in liver scarring and resolution of MASH among patients receiving semaglutide compared to placebo. Despite the promising findings, analysts remain cautious about its competitive edge in the MASH treatment landscape.
The 2025 Medicare Advantage star ratings reveal a decline for major insurers like UnitedHealth and Humana, with Humana experiencing the largest drop at 0.74 stars. In contrast, insurtechs like Clover Health and Alignment Healthcare saw significant improvements, with Clover achieving a 4-star rating for its PPO offering. As open enrollment approaches, Humana is contesting its scores, while UnitedHealth is pursuing legal action over a call center issue.
Upstream Bio has priced its IPO at $255 million, selling 15 million shares at $17 each, to fund the development of its antibody drug targeting respiratory diseases. The company aims to challenge existing asthma treatments, with plans to report Phase 2 results for its drug, verekitug, in 2025. This IPO reflects a growing investor interest in immunology-focused biotech firms, with a notable increase in offerings this year.
William Blair
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
novo seeks approval for semaglutide as treatment for liver disease
United States Dollar
Eli Lilly and Company
Akero Therapeutics, Inc.
Novo Nordisk A/S
Zealand Pharma A/S
Intercept Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc.
Boehringer Ingelheim KG
89bio, Inc.
DNK
Thomas Smith
Andy Hsieh
Brian Abrahams
Martin Holst Lange
William Blair
Show more
15:45 01.11.2024
medicare advantage star ratings 2025 reveal winners and losers in healthcare
Cigna Corporation
Humana Inc.
UnitedHealth Group Incorporated
CVS Health Corporation
Centene Corporation
USA
William Blair
Jamie Reynoso
Show more
21:28 11.10.2024
upstream bio raises 255 million in ipo to develop asthma drug
United States Dollar
Upstream Bio, Inc.
Camp4 Therapeutics Corporation
AstraZeneca PLC
Astellas Pharma Inc.
Amgen Inc.
USA
William Blair
Astellas Pharma
Show more
02:07 11.10.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Financial Scams and Security
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Market Analysis and Predictions
Hedge Funds & Private Equity
Retail and Consumer Goods
Supply Chain Management
Workplace Trends
Startups & Entrepreneurship
CEO Changes
Global Trade Developments
Cryptocurrency Trends
Real Estate Investments
Government Economic Policies
Venture Capital Investments
Consumer Protection Regulations
Countries:
Companies:
JPMorgan Chase & Co.
Barclays PLC
Bank of America Corporation
The Goldman Sachs Group, Inc.
Tesla, Inc.
Citigroup Inc.
Geode Capital Management LLC
Morgan Stanley
The Charles Schwab Corporation
Charles Schwab Investment Management Inc.
Wells Fargo & Company
NVIDIA Corporation
Credit Suisse Real Estate Fund Siat
State Street Corporation
Broadcom Inc.
Deutsche Bank Aktiengesellschaft
Apple Inc.
Tesmec S.p.A.
Lloyds Banking Group plc
HSBC Holdings plc
Currencies:
United States Dollar
Swiss Franc
British Pound Sterling
Chinese Yuan
Euro
Indian Rupee
United Arab Emirates Dirham
South Korean Won
Offshore Chinese Yuan
Japanese Yen
Azerbaijani Manat
New Taiwan Dollar
Saudi Riyal
Singapore Dollar
Vietnamese Đồng
People: